Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EQ |
---|---|---|
09:32 ET | 101 | 0.7266 |
09:38 ET | 937 | 0.7071 |
09:41 ET | 200 | 0.7 |
09:45 ET | 1669 | 0.7071 |
09:50 ET | 1200 | 0.718399 |
09:54 ET | 300 | 0.7184 |
09:57 ET | 3350 | 0.697101 |
10:12 ET | 614 | 0.7001 |
10:28 ET | 1000 | 0.7004 |
10:33 ET | 2453 | 0.7003 |
10:37 ET | 2500 | 0.70925 |
10:42 ET | 500 | 0.7003 |
10:46 ET | 1001 | 0.70925 |
10:48 ET | 600 | 0.7004 |
10:50 ET | 1195 | 0.71 |
11:09 ET | 127 | 0.7101 |
11:11 ET | 2000 | 0.7101 |
11:15 ET | 100 | 0.7101 |
11:24 ET | 1354 | 0.7101 |
11:26 ET | 100 | 0.7102 |
11:27 ET | 100 | 0.7102 |
11:38 ET | 334 | 0.7102 |
11:40 ET | 2133 | 0.719 |
11:45 ET | 1460 | 0.719 |
12:00 ET | 195 | 0.72 |
12:20 ET | 1389 | 0.72 |
12:23 ET | 450 | 0.7104 |
12:30 ET | 100 | 0.7104 |
12:39 ET | 632 | 0.7102 |
12:57 ET | 10000 | 0.7101 |
01:15 ET | 2000 | 0.7102 |
01:26 ET | 3274 | 0.7104 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Equillium Inc | 25.3M | -2.0x | --- |
Microalliance Group Inc | 36.6M | 4.4x | --- |
CASI Pharmaceuticals Inc | 38.3M | -1.2x | --- |
Biofrontera Inc | 5.2M | -0.1x | --- |
Health-Chem Corp | 1.2K | 0.0x | --- |
Bon Natural Life Ltd | 9.1M | 0.5x | +78.05% |
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $25.3M |
---|---|
Revenue (TTM) | $37.9M |
Shares Outstanding | 35.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.81 |
EPS | $-0.35 |
Book Value | $0.64 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -34.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.